Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Microbial diols, polyols, and phosphate-containing metabolites refers to a diverse set of small-molecule antigens derived from microbial metabolic pathways that are recognized by the human immune system through specialized non-polymorphic molecules (Kjer-Nielsen et al., 2012, Nature). This category primarily includes riboflavin (vitamin B2) biosynthesis intermediates, such as the polyol 5-OP-RU, which are presented by MHC-related protein 1 (MR1) to activate Mucosal-Associated Invariant T (MAIT) cells (Corbett et al., 2014, Nature). Additionally, it encompasses phosphate-containing metabolites known as phosphoantigens, such as (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), which are sensed by the intracellular domain of Butyrophilin 3A1 (BTN3A1) to trigger the activation of Vγ9Vδ2 T cells (Vantourout et al., 2013, Cancer Research). These metabolites serve as molecular signatures of infection and metabolic stress, allowing unconventional T cells to rapidly respond to pathogens and malignant cells. While these metabolites are ligands rather than therapeutic targets themselves, the pathways they activate are being exploited for immunotherapy. For instance, aminobisphosphonates like zoledronic acid are used to increase endogenous phosphoantigen levels to stimulate anti-tumor gamma-delta T cell activity, and synthetic analogs are being developed as potent vaccine adjuvants or direct T-cell activators (Rigau et al., 2020, Immunity).
Activation of unconventional T cells through stabilization of MR1 or BTN3A1; Inhibition of the mevalonate pathway to increase endogenous phosphoantigen levels.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Microbial diols, polyols, and phosphate-containing metabolites.